Abstract
The pharmacological effects of morphine and morphine-like drugs are mediated primarily through the µ opioid receptor. Here we show that differential use of an in-frame translational start codon in the 5′-untranslated region of the OPRM1 generates different translational products in vivo and in vitro. The 5′-end of the OPRM1 gene is necessary for initiating the alternate form and for subsequent degradation of the protein. Initiation of OPRM1 at the upstream site decreases the initiation at the main AUG site. However, alternative initiation of the long form of OPRM1 produces a protein with a short half-life, resulting from degradation mediated by the ubiquitin–proteasome pathway. Reporter and degradation assays showed that mutations of this long form at the second and third lysines reduce ubiquitin-dependent proteasome degradation, stabilizing the protein. The data suggest that MOP expression is controlled in part by initiation of the long form of MOP at the alternate site.
Similar content being viewed by others
References
Chaturvedi K, Christoffers KH, Singh K, Howells RD (2001) Structure and regulation of opioid receptors. Biopolymers 55:334–346
Min BH, Augustin LB, Felsheim RF, Fuchs JA, Loh HH (1994) Genomic structure analysis of promoter sequence of a mouse μ opioid receptor gene. Proc Natl Acad Sci USA 91:9081–9085
Kieffer B (1995) Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 15:615–635
Kieffer B (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19–26
Kim CS, Hwang CK, Choi HS, Song KY, Law PY, Wei LN, Loh HH (2004) Neuron-restrictive silencer factor (NRSF) functions as a repressor in neuronal cells to regulate the mu opioid receptor gene. J Biol Chem 279:46464–46473
Choi HS, Hwang CK, Kim CS, Song KY, Law PY, Wei LN, Loh HH (2005) Transcriptional regulation of mouse mu opioid receptor gene: Sp3 isoforms (M1, M2) function as repressors in neuronal cells to regulate the mu opioid receptor gene. Mol Pharmacol 67:1674–1683
Choi HS, Kim CS, Hwang CK, Song KY, Wang W, Qiu Y, Law PY, Wei LN, Loh HH (2006) The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem Biophys Res Commun 343:1132–1140
Kim CS, Choi HS, Hwang CK, Song KY, Lee BK, Law PY, Wei LN, Loh HH (2006) Evidence of the neuron-restrictive silencer factor (NRSF) interaction with Sp3 and its synergic repression to the mu opioid receptor (MOR) gene. Nucleic Acids Res 34:6392–6403
Hwang CK, Song KY, Kim CS, Choi HS, Guo XH, Law PY, Wei LN, Loh HH (2007) Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters. Mol Cell Biol 27:4720–4736
Choi HS, Kim CS, Hwang CK, Song KY, Law PY, Wei LN, Loh HH (2007) Novel function of the poly(C)-binding protein alpha CP3 as a transcriptional repressor of the mu opioid receptor gene. FASEB J 21:3963–3973
Choi HS, Hwang CK, Kim CS, Song KY, Law PY, Loh HH, Wei LN (2008) Transcriptional regulation of mouse mu opioid receptor gene in neuronal cells by poly(ADP-ribose) polymerase-1. J Cell Mol Med 12:2319–2333
Choi HS, Song KY, Hwang CK, Kim CS, Law PY, Wei LN, Loh HH (2008) A proteomics approach for identification of single strand DNA-binding proteins involved in transcriptional regulation of mouse mu opioid receptor gene. Mol Cell Proteomics 7:1517–1529
Wei LN, Law PY, Loh HH (2004) Post-transcriptional regulation of opioid receptors in the nervous system. Front Biosci 9:1665–1679
Song KY, Hwang CK, Kim CS, Choi HS, Law PY, Wei LN, Loh HH (2007) Translational repression of mouse mu opioid receptor expression via leaky scanning. Nucleic Acids Res 35:1501–1513
Song KY, Kim CS, Hwang CK, Choi HS, Law PY, Wei LN, Loh HH (2009) uAUG-mediated translational initiations are responsible for human mu opioid receptor gene expression. J Cell Mol Med (in press)
Uhlmann-Schiffler H, Rössler OG, Stahl H (2002) The mRNA of DEAD box protein p72 is alternatively translated into an 82-kDa RNA helicase. J Biol Chem 277:1066–1075
Aviel S, Winberg G, Massucci M, Ciechanover A (2000) Degradation of the Epstein–Barr virus latent membrane protein 1 (LMP1) by the ubiquitin–proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J Biol Chem 275:23491–23499
Reinstein E, Scheffner M, Oren M, Ciechanover A, Schwartz A (2000) Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin–proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 19:5944–5950
Glickman MH, Ciechanover A (2002) The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373–428
Laney JD, Hochstrasser M (1999) Substrate targeting in the ubiquitin system. Cell 97:427–430
Ciechanover A, Schwartz AL (1998) The ubiquitin–proteasome pathway: the complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 95:2727–2730
Kornilova E, Sorkina T, Beguinot L, Sorkin A (1996) Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues 1022–1123. J Biol Chem 271:30340–30346
Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ (2001) Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294:1307–1313
Madura K, Varshavsky A (1994) Degradation of G alpha by the N-end rule pathway. Science 265:1454–1458
Chaturvedi K, Bandari P, Chinen N, Howells RD (2001) Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J Biol Chem 276:12345–12355
Kochetov AV (2008) Alternative translation start sites and hidden coding potential of eukaryotic mRNAs. Bioessays 30:683–691
Crowe ML, Wang XQ, Rothnagel JA (2006) Evidence for conservation and selection of upstream open reading frames suggests probable encoding of bioactive peptides. BMC Genomics 7:16
Galagan JE, Calvo SE, Cuomo C, Ma LJ, Wortman JR, Batzoglou S, Lee SI, Batürkmen M, Spevak CC, Clutterbuck J, Kapitonov V, Jurka J, Scazzocchio C, Farman M, Butler J, Purcell S, Harris S, Braus GH, Draht O, Busch S, D’Enfert C, Bouchier C, Goldman GH, Bell-Pedersen D, Griffiths-Jones S, Doonan JH, Yu J, Vienken K, Pain A, Freitag M, Selker EU, Archer DB, Peñalva MA, Oakley BR, Momany M, Tanaka T, Kumagai T, Asai K, Machida M, Nierman WC, Denning DW, Caddick M, Hynes M, Paoletti M, Fischer R, Miller B, Dyer P, Sachs MS, Osmani SA, Birren BW (2005) Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature 438:1105–1115
Ivanov IP, Loughran G, Atkins JF (2008) uORFs with unusual translational start codons autoregulate expression of eukaryotic ornithine decarboxylase homologs. Proc Natl Acad Sci USA 105:10079–10084
Kochetov AV, Ahmad S, Ivanisenko V, Volkova OA, Kolchanov NA, Sarai A (2008) uORFs, reinitiation and alternative translation start sites in human mRNAs. FEBS Lett 582:1293–1297
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479
Hicke L, Dunn R (2003) Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19:141–172
Ciechanover A (2006) Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin–proteasome system and onto human diseases and drug targeting. Exp Biol Med (Maywood) 231:1197–1211
Vembar S, Brodsky JL (2008) One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 12:944–957
Sitia R, Braakman I (2003) Quality control in the endoplasmic reticulum protein factory. Nature 426:891–894
Anelli T, Sitia R (2008) Protein quality control in the early secretory pathway. EMBO J 27:315–327
Leskelä T, Markkanen PM, Alahuhta IA, Tuusa JT, Petäjä-Repo UE (2009) Phe27Cys polymorphism alters the maturation and subcellular localization of the human delta opioid receptor. Traffic 10:116–129
Schwieger I, Lautz K, Krause E, Rosenthal W, Wiesner B, Hermosilla R (2008) Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors. Mol Pharmacol 73:697–708
Acknowledgments
This work was supported by National Institutes of Health research grants DA000564, DA001583, DA011806, K05-DA070554, DA011190, and DA013926, and by the A&F Stark Fund of the Minnesota Medical Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Song, K.Y., Choi, H.S., Hwang, C.K. et al. Differential use of an in-frame translation initiation codon regulates human mu opioid receptor (OPRM1). Cell. Mol. Life Sci. 66, 2933–2942 (2009). https://doi.org/10.1007/s00018-009-0082-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-009-0082-7